Supplementary Methods, Tables, and Figure from Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring &lt;i&gt;FGF&lt;/i&gt;/&lt;i&gt;FGFR&lt;/i&gt; Aberrations: A Phase I Dose-Expansion Study